WH
WHWK
Whitehawk Therapeutics, Inc.
$4.02
-3.13%
$216.2M
No data for this timeframe.
Vol
Market Cap$216.2M
Cap SizeMicro Cap
Analyst ConsensusBuy (67%)
Inst. Holders5 funds
Inst. Value$5.7M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 14S
Insider Net $-$2.6M
SEC Reports7
Recent Activity
May 29, 2026
SEC
Whitehawk Therapeutics filed an S-3 registration statement to register 22,321,887 shares for resale by selling stockhold
S-3 — Impact 6/10
May 14, 2026
Insider
Dugan Margaret sold 19,132 shares
Chief Medical Officer @ $3.92 ($75.0K)
May 14, 2026
Insider
Lennon David James sold 51,021 shares
CHIEF EXECUTIVE OFFICER @ $3.92 ($200.0K)
May 14, 2026
Insider
Castelein Caley sold 255,102 shares
Director @ $3.92 ($1000.0K)
May 13, 2026
SEC
Whitehawk Therapeutics announced an $87.5M PIPE financing, selling 4,330,866 shares at $3.92/share and 17,991,021 pre-fu
8-K — Impact 8/10
May 7, 2026
SEC
Whitehawk Therapeutics reported Q1 2026 results: net loss of $22.2M ($-0.32/share) vs consensus $-0.33, a 3% beat. Reven
8-K — Impact 3/10
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
309,865 shares ($749.9K)
Inst.
MORGAN STANLEY — DOUBLED
6,748 shares ($16.3K)
Price Targets
$6.50
+54.0% upside
Strong Buy
Current $4.22
Low $4.00
Median $7.00
High $8.00
4 analysts
$4.00
$8.00
Analyst Ratings
3Strong Buy
5Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 16, 2026 | Citizens | INITIATE | Market Outperform |
| Dec 22, 2025 | Jones Trading | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.27 | $-0.27 — $-0.27 | 64% YoY | 2 |
| Next Q | $-0.30 | $-0.32 — $-0.28 | -18% YoY | 2 |
| Current FY | $-1.17 | $-1.21 — $-1.12 | 33% YoY | 2 |
| Next FY | $-1.23 | $-1.26 — $-1.19 | -5% YoY | 2 |
Latest Reports
BEARISH
S-3
6/10
Whitehawk Therapeutics filed an S-3 registration statement to register 22,321,887 shares for resale by selling stockhold
May 29, 2026
BEARISH
8-K
8/10
Whitehawk Therapeutics announced an $87.5M PIPE financing, selling 4,330,866 shares at $3.92/share and 17,991,021 pre-fu
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $3.8M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | — |
| TWO SIGMA INVESTMENTS, LP | $749.9K | NEW |
| MORGAN STANLEY | $16.3K | DOUBLED |
| BANK OF AMERICA CORP | $995.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Dugan Margaret | A | $75.0K |
| May 14, 2026 | Lennon David | A | $200.0K |
| May 14, 2026 | Castelein Caley | A | $1000.0K |
| May 14, 2026 | Giacobello Scott | A | $150.0K |
| May 14, 2026 | Castelein Caley | A | $16.8T |
5 institutional holders with $5.7M total value (2,347,863 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,590,117 | $3.8M | 67.7% | ADD +71.7% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 440,722 | $1.1M | 18.8% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 309,865 | $749.9K | 13.2% | NEW |
| 4 | MORGAN STANLEY | 6,748 | $16.3K | 0.3% | DOUBLED +265.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 411 | $995.00 | 0.0% | DOUBLED +793.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | NEW | — | 309,865 | — | $749.9K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,849 | 6,748 | +265.0% | $16.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 46 | 411 | +793.5% | $995.00 | 2025-Q4 |
| UBS Group AG | TRIM | 8,673 | 5,693 | -34.4% | $10.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 411 | 46 | -88.8% | $87.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 765,992 | 1,315,285 | +71.7% | $2.5M | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 35,567 | 8,673 | -75.6% | $16.2K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 64,237 | 2,003 | -96.9% | $3.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 180 | 411 | +128.3% | $769.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 43,158 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 80,135 | 102,012 | +27.3% | $181.6K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 12,761 | 64,237 | +403.4% | $114.3K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 68,555 | 43,158 | -37.0% | $76.8K | 2025-Q1 |
| UBS Group AG | TRIM | 59,174 | 35,567 | -39.9% | $63.3K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 600 | 33 | -94.5% | $59.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 31,244 | 80,135 | +156.5% | $252.8K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 2,411 | 12,761 | +429.3% | $40.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,822 | 600 | -78.7% | $1.9K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 64,904 | 2,411 | -96.3% | $5.0K | 2024-Q3 |
7 unique insiders with 14 transactions. Net insider value: -$2.6M ($0.00 bought, $2.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Dugan Margaret | Chief Medical Officer | A | 19,132 | $3.92 | $75.0K |
| May 14, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | A | 51,021 | $3.92 | $200.0K |
| May 14, 2026 | Castelein Caley | Director | A | 255,102 | $3.92 | $1000.0K |
| May 14, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | A | 38,265 | $3.92 | $150.0K |
| May 14, 2026 | Castelein Caley | Director | A | 2,072,756 | $8,124,996.24 | $16.8T |
| May 14, 2026 | BALL BRYAN | See remarks | A | 51,020 | $3.92 | $200.0K |
| May 12, 2026 | Avoro Capital Advisors LLC | Director | A | 6,377,714 | $3.92 | $25.0M |
| Apr 16, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | SELL | 141,600 | $4.13 | $584.8K |
| Apr 15, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | SELL | 77,000 | $3.86 | $297.2K |
| Apr 14, 2026 | BALL BRYAN | See remarks | SELL | 92,460 | $3.64 | $336.6K |
| Apr 13, 2026 | BALL BRYAN | See remarks | SELL | 26,389 | $3.46 | $91.3K |
| Apr 10, 2026 | BALL BRYAN | See remarks | SELL | 6,596 | $3.43 | $22.6K |
| Apr 9, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | SELL | 14,500 | $3.38 | $49.0K |
| Apr 9, 2026 | BALL BRYAN | See remarks | SELL | 50,000 | $3.57 | $178.5K |
| Apr 8, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | SELL | 63,945 | $3.40 | $217.4K |
| Apr 7, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | SELL | 94,087 | $3.43 | $322.7K |
| Apr 6, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | SELL | 102,395 | $3.51 | $359.4K |
| Apr 2, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | SELL | 26,858 | $3.48 | $93.5K |
| Apr 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | M | 775,828 | $0.00 | $0.00 |
| Apr 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | M | 775,828 | $0.00 | $0.00 |
| Apr 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | A | 831,148 | $0.00 | $0.00 |
| Apr 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | M | 473,902 | $0.00 | $0.00 |
| Apr 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | M | 473,902 | $0.00 | $0.00 |
| Apr 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | A | 300,677 | $0.00 | $0.00 |
| Apr 1, 2026 | BALL BRYAN | See remarks | M | 366,532 | $0.00 | $0.00 |
| Apr 1, 2026 | BALL BRYAN | See remarks | M | 366,532 | $0.00 | $0.00 |
| Apr 1, 2026 | BALL BRYAN | See remarks | A | 250,058 | $0.00 | $0.00 |
| Apr 1, 2026 | Dugan Margaret | Chief Medical Officer | A | 283,157 | $0.00 | $0.00 |
| Apr 1, 2026 | Dornan David | Chief Scientific Officer | A | 282,340 | $0.00 | $0.00 |
| Mar 2, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | SELL | 5,100 | $3.31 | $16.9K |
| Mar 2, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | SELL | 2,594 | $3.31 | $8.6K |
| Mar 2, 2026 | BALL BRYAN | See remarks | SELL | 1,834 | $3.31 | $6.1K |
| Mar 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | M | 16,250 | $0.00 | $0.00 |
| Mar 1, 2026 | Lennon David James | CHIEF EXECUTIVE OFFICER | M | 16,250 | $0.00 | $0.00 |
| Mar 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | M | 6,750 | $0.00 | $0.00 |
| Mar 1, 2026 | Giacobello Scott M. | CHIEF FINANCIAL OFFICER | M | 6,750 | $0.00 | $0.00 |
| Mar 1, 2026 | BALL BRYAN | See remarks | M | 5,000 | $0.00 | $0.00 |
| Mar 1, 2026 | BALL BRYAN | See remarks | M | 5,000 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 5 bearish, 0 mixed, 2 neutral. Avg impact: 5.9/10.
BEARISH
S-3
6/10
Whitehawk Therapeutics filed an S-3 registration statement to register 22,321,887 shares for resale
May 29, 2026
BEARISH
8-K
8/10
Whitehawk Therapeutics announced an $87.5M PIPE financing, selling 4,330,866 shares at $3.92/share a
May 13, 2026
NEUTRAL
8-K
3/10
Whitehawk Therapeutics reported Q1 2026 results: net loss of $22.2M ($-0.32/share) vs consensus $-0.
May 7, 2026
BEARISH
CLUSTER
7/10
Three corporate insiders at Whitehawk Therapeutics, including the CEO and CFO, sold shares in a coor
Apr 17, 2026
BEARISH
CLUSTER
6/10
Two corporate insiders at Whitehawk Therapeutics, including CEO David James Lennon, sold shares in o
Apr 16, 2026
BEARISH
CLUSTER
7/10
Whitehawk Therapeutics CEO David James and insider Bryan Ball collectively sold $228,000 worth of sh
Apr 14, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 12, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (67% buy). Based on 12 analysts: 3 strong buy, 5 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.50 mean target
+54.0% upside
Strong Buy (2.17)
$4.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $4.22 |
| Target Low | $4.00 |
| Target Mean | $6.50 |
| Target Median | $7.00 |
| Target High | $8.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (2.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.27 | $-0.27 | $-0.27 | 64.5% | — | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.30 | $-0.32 | $-0.28 | -18.2% | — | — | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.17 | $-1.21 | $-1.12 | 33.2% | — | 0↑ 1↓ | $0.0B | -100.0% | 2 |
| Next FY 2027-12-31 |
$-1.23 | $-1.26 | $-1.19 | -5.1% | — | 0↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.270 | |
| 7d ago | $-0.270 | |
| 30d ago | $0.000 | -0.270 |
| 60d ago | $-0.305 | +0.035 |
| 90d ago | $-0.280 | +0.010 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 16, 2026 | Citizens | INITIATE | — | Market Outperform |
| Dec 22, 2025 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| May 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| Apr 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Mar 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Feb 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Jan 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
WHWK Q1 2026 Earnings Scheduled — 2026-05-07
Mar 12, 2026
earnings_calendar
WHWK Q4 2025 Earnings After Market Close — 2026-03-12